Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DTP3 in relapsed or refractory multiple myeloma or diffuse large B-cell lymphoma
ISRCTN13777452Phase 2Recruiting
- Sponsor
- Imperial College London
- Start
- May 2022
- Modality
- Small Molecules, Peptides
01
Overview
Phase 2, open-label trial of DTP3 in multiple myeloma (MM) and diffuse large B-cell lymphoma (DLBCL), sponsored by Imperial College London. Primary endpoints: Safety and tolerability, Overall response rate and 2 more. Started May 2022; status: recruiting.
02
Drugs
DTP3
03
Conditions
multiple myeloma (MM)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ISRCTN13777452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN13777452.